Bots, editor, reviewer, Administrators
13,951
edits
Feed:All articles/Pretty: Difference between revisions
Jump to navigation
Jump to search
no edit summary
No edit summary |
No edit summary |
||
| Line 1,370: | Line 1,370: | ||
"title" : "Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: The BASALT randomized controlled trial", | "title" : "Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: The BASALT randomized controlled trial", | ||
"pmid" : "22968888" | "pmid" : "22968888" | ||
}, | |||
{ | |||
"timestamp" : "2023-12-14T19:36:06Z", | |||
"briefDesignDescription" : "Tisa-cel vs. ASCT in R/R DLBCL", | |||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa2116596", | |||
"pageid" : 4462, | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2116596", | |||
"trainingLevel" : "Fellow", | |||
"citation" : "Bishop MR, <i>et al</i>. \"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma\". <i>The New England Journal of Medicine</i>. 2022. 368(7):629-639.", | |||
"subspecialties" : "Hematology;Oncology", | |||
"expansion" : "", | |||
"statusUsableDate" : "2023-12-14", | |||
"briefResultsDescription" : "CART did not improve PFS compared to ASCT", | |||
"published" : "2022-02-17", | |||
"pageName" : "BELINDA", | |||
"diseases" : "Lymphoma;Aggressive B-cell lymphoma", | |||
"abbreviation" : "BELINDA", | |||
"title" : "Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma", | |||
"pmid" : "34904798" | |||
}, | }, | ||
{ | { | ||